Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 65.26M | 69.21M | 66.98M | 65.32M | 64.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.26M | 69.21M | 66.98M | 65.32M | 64.81M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 65.26M | 69.21M | 66.98M | 65.32M | 64.81M |
| SG&A Expenses | 37.75M | 38.28M | 40.10M | 43.93M | 47.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.99M | 129.60M | 140.04M | 150.67M | 161.62M |
| Operating Income | -58.73M | -60.38M | -73.06M | -85.35M | -96.82M |
| Income Before Tax | -63.13M | -61.89M | -72.76M | -83.55M | -94.07M |
| Income Tax Expenses | 99.00K | 92.00K | -1.22M | -1.66M | -2.06M |
| Earnings from Continuing Operations | -63.23 | -61.98 | -71.54 | -81.89 | -92.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.23M | -61.98M | -71.54M | -81.89M | -92.01M |
| EBIT | -58.73M | -60.38M | -73.06M | -85.35M | -96.82M |
| EBITDA | -53.82M | -55.45M | -68.13M | -80.76M | -93.04M |
| EPS Basic | -2.41 | -2.59 | -3.20 | -3.84 | -4.32 |
| Normalized Basic EPS | -1.53 | -1.65 | -2.07 | -2.46 | -2.78 |
| EPS Diluted | -2.41 | -2.59 | -3.20 | -3.84 | -4.32 |
| Normalized Diluted EPS | -1.53 | -1.65 | -2.07 | -2.46 | -2.78 |
| Average Basic Shares Outstanding | 108.26M | 100.55M | 92.86M | 85.35M | 85.16M |
| Average Diluted Shares Outstanding | 108.26M | 100.55M | 92.86M | 85.35M | 85.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |